Merck to Present New Data for Investigational Hepatitis C Treatments...

Merck , known as MSD outside the United States and Canada, announced today that new Phase 2 data for its two investigational hepatitis C virus treatments - MK-5172, an investigational HCV NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor - are scheduled to be presented at the 49th Annual Meeting of ... (more)

http://ift.tt/1nU6BdL